The Medical Letter - 2019
Search or Select Article Below and Click to Purchase
Year:    Publication:     
April 22, 2019 (Issue 1570)  
April 8, 2019 (Issue 1569)  
March 25, 2019 (Issue 1568)  
March 11, 2019 (Issue 1567)  
February 25, 2019 (Issue 1566)  
February 11, 2019 (Issue 1565)  
January 28, 2019 (Issue 1564)  
  • OTC Primatene Mist Returns
    The FDA has approved over-the-counter (OTC) sale of inhaled epinephrine (Primatene Mist – Amphastar), a nonselective alpha and beta agonist, for temporary relief of mild symptoms of...
  • Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis
    Qbrexza (Dermira), a premoistened cloth containing the long-acting anticholinergic drug glycopyrronium, has been approved by the FDA for once-daily topical treatment of excessive underarm...
  • Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation
    The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first...
  • Revefenacin (Yupelri) for COPD
    The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance...
  • Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
    Monitoring adherence of psychiatric patients to oral medication may be especially difficult. The FDA has approved Abilify MyCite (Otsuka/Proteus), an aripiprazole tablet with an embedded...
January 14, 2019 (Issue 1563)